Oxford BioDynamics signs first pharmaceutical EpiSwitch Orion agreement with Johnson & Johnson

Oxford BioDynamics has secured its first pharmaceutical-company agreement for the EpiSwitch Orion platform, partnering with Johnson & Johnson on inflammatory bowel disease biomarker discovery.

The commercial agreement announced on 5 November 2026 will apply Oxford BioDynamics' cloud-based EpiSwitch Orion 3D-genomics technology to research seeking baseline genomic biomarkers that may predict patient response to a biologic therapy for inflammatory bowel disease.

The partnership follows an earlier academic Orion commercial agreement announced in July 2026 and represents a new pharmaceutical research application, with financial terms undisclosed and no diagnostic approval or therapeutic licensing rights announced.

Field	Content
Article Type	Deals
Company	Oxford BioDynamics
Pharmaceutical Partner	Johnson & Johnson
Deal Type	Commercial biomarker research agreement
Announcement Date	5 November 2026
Transaction Status	Agreement announced
Technology Platform	EpiSwitch Orion
Platform Delivery	Cloud-based
Technology Type	3D-genomics biomarker discovery
Research Focus	Baseline genomic biomarkers associated with treatment response
Therapeutic Area	Gastroenterology
Disease Area	Inflammatory bowel disease
Treatment Class Studied	Biologic therapy
Specific Biologic	Not disclosed in supplied summary
Research Objective	Identify genomic biomarkers potentially predictive of patient response to biologic treatment
Pharmaceutical Customer	Johnson & Johnson
Commercial Milestone	First pharmaceutical-company agreement for EpiSwitch Orion
Previous Orion Commercial Agreement	Academic agreement announced in July 2026
Financial Consideration	Not disclosed
Licensing Structure	Commercial research arrangement; detailed financial and intellectual property terms not disclosed
Regulatory Status	No new diagnostic regulatory approval announced
Drug Licensing Status	No new therapeutic licence announced
Clinical Validation Status	Not established by the supplied agreement summary
What Happened	Oxford BioDynamics signed its first pharmaceutical-company agreement for EpiSwitch Orion with Johnson & Johnson.
Why It Matters	The agreement extends commercial use of a 3D-genomics biomarker platform into pharmaceutical research aimed at improving understanding of treatment response.
Strategic Rationale	Apply genomic biomarker discovery technology to support precision-medicine research in inflammatory bowel disease.
Transaction Distinction	Commercial biomarker research agreement rather than an approved diagnostic or drug licensing transaction.
Key Takeaway	Johnson & Johnson will use EpiSwitch Orion in an inflammatory bowel disease biomarker-discovery programme.
What to Watch	Biomarker findings, subsequent validation, expansion of pharmaceutical partnerships and potential clinical research applications.
Primary Source	Oxford BioDynamics announcement
Primary Source URL	https://www.investegate.co.uk/announcement/rns/oxford-biodynamics--obd/first-pharma-agreement-for-episwitch-orion/9859325
Relevant Date	5 November 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

• Contact us on: support@nuaxia.com